Exogenous Alanine and/or Glucose plus Kanamycin Kills Antibiotic-Resistant Bacteria  by Peng, Bo et al.
ArticleExogenous Alanine and/or Glucose plus Kanamycin
Kills Antibiotic-Resistant BacteriaGraphical AbstractHighlightsd Glucose and alanine abundances are suppressed in
kanamycin-resistant E. tarda
d Alanine or glucose, via the TCA cycle, restores bacterial
susceptibility to antibiotics
d NADH and proton motive force increases, which stimulates
uptake of antibiotic
d A functional metabolomics-based strategy to kill bacteria is
developedPeng et al., 2015, Cell Metabolism 21, 249–261
February 3, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cmet.2015.01.008Authors
Bo Peng, Yu-bin Su, ..., Yao-mei Tian,
Xuan-xian Peng
Correspondence
pxuanx@sysu.edu.cn
In Brief
Peng et al. show that exogenous alanine
and/or glucose restores susceptibility to
antibiotics in antibiotic-resistant bacteria
by increasing TCA flux, NADHproduction,
and proton motive force to enhance
kanamycin uptake, both in vitro and in a
mouse model for urinary tract infection.
Cell Metabolism
ArticleExogenous Alanine and/or Glucose
plus Kanamycin Kills
Antibiotic-Resistant Bacteria
Bo Peng,1,2,3 Yu-bin Su,1,3 Hui Li,1,3 Yi Han,1 Chang Guo,1 Yao-mei Tian,1 and Xuan-xian Peng1,*
1Center for Proteomics and Metabolomics, State Key Laboratory of Biocontrol, School of Life Sciences, MOE Key Lab Aquat Food Safety,
School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, People’s Republic of China
2Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8197, USA
3Co-first author
*Correspondence: pxuanx@sysu.edu.cn
http://dx.doi.org/10.1016/j.cmet.2015.01.008SUMMARY
Multidrug-resistant bacteria are an increasingly
serious threat to human and animal health. However,
novel drugs that can manage infections by multi-
drug-resistant bacteria have proved elusive. Here
we show that glucose and alanine abundances are
greatly suppressed in kanamycin-resistant Edward-
siella tarda by GC-MS-based metabolomics. Exoge-
nous alanine or glucose restores susceptibility of
multidrug-resistant E. tarda to killing by kanamycin,
demonstrating an approach to killing multidrug-
resistant bacteria. The mechanism underlying this
approach is that exogenous glucose or alanine pro-
motes the TCA cycle by substrate activation, which
in turn increases production of NADH and proton
motive force and stimulates uptake of antibiotic.
Similar results are obtained with other Gram-nega-
tive bacteria (Vibrio parahaemolyticus, Klebsiella
pneumoniae, Pseudomonas aeruginosa) and Gram-
positive bacterium (Staphylococcus aureus), and
the results are also reproduced in a mouse model
for urinary tract infection. This study establishes a
functional metabolomics-based strategy to manage
infection by antibiotic-resistant bacteria.
INTRODUCTION
Bacterial antibiotic resistance is a threat to human health and to
the viability of animal and plant species in the human food chain.
Because efforts to develop antimicrobials that kill multidrug-
resistant bacteria have not been successful to date (Raju et al.,
2012; Coates and Hu, 2007), there is an urgent need and high
demand for agents that can kill or prevent infection with these
bacteria. Unfortunately, the existing arsenal of antibiotics no
longer provides protection against infection with Gram-negative
bacteria and other pathogenic bacterial species or subspecies
(Piddock, 2012; Carlet et al., 2012). It has been noted that antibi-
otics tend to achieve a lower intracellular concentration in antibi-
otic-resistant bacteria than in closely related antibiotic-sensitiveCell Mstrains, indicating either lower rate of drug uptake or higher rate
of drug exported (or both) (Page`s et al., 2008; Alekshun and
Levy, 2007). To overcome this phenomenon, novel approaches
must be developed to achieve an intracellular drug concentra-
tion sufficiently high that the intended biological effect is
observed (Hancock et al., 2012; Lee and Collins, 2012; Roemer
and Boone, 2013).
Some evidence suggests that agents that increase the trans-
membrane protonmotive force (PMF) stimulate uptake of amino-
glycoside antibiotics (Allison et al., 2011; Wang et al., 2009). We
propose that the metabolic state of a bacterium significantly in-
fluences its relative susceptibility to killing by antibiotic drugs,
and that specific metabolic profiles correlate with antibiotic
resistance. Furthermore, reagents that revert the metabolome
of an antibiotic-resistant strain to that of an antibiotic-sensitive
strain could potentially revert the phenotype of antibiotic resis-
tance. In particular, we propose that exogenous metabolites
might have this effect, if they increase transmembrane PMF,
converting drug-resistant bacteria to drug-sensitive bacteria.
Edwardsiella tarda is represented in the normal gut flora of
humans and fish, but it is also an opportunistic intracellular
pathogen in humans, fish, and other species (Haenen et al.,
2013; Park et al., 2012). In humans, E. tarda can cause gastroen-
teritis, colitis, dysentery-like disease, septicemia, and meningitis
(Nelson et al., 2009; Kawai et al., 2011). Infants can become in-
fected with E. tarda during birth (Mowbray et al., 2003), and it
has been linked to devastating declines in fish populations
(Park et al., 2012; Liu et al., 2013). Multidrug-resistant E. tarda
has been isolated from fish and human (Wang et al., 2009; Yu
et al., 2012; Kawai et al., 2011), presenting significant challenge
for its control. Here, we describe the metabolic state of antibi-
otic-resistant E. tarda and demonstrate that exogenous alanine
or glucose revert the bacterium to kanamycin susceptibility.
RESULTS
Metabolic Profile and Potential Biomarkers of
Drug-Resistant E. tarda
To study antibiotic resistance in E. tarda, wild-type kanamycin-
susceptible E. tarda LTB4 (LTB4-S) were grown in media con-
taining kanamycin. Single cells that survived and proliferated
in the presence of the antibiotic were used to establish a homog-
enous kanamycin-resistant cell line, and kanamycin-resistantetabolism 21, 249–261, February 3, 2015 ª2015 Elsevier Inc. 249
E. tarda LTB4 (LTB4-R) were selected (Figure S1A). Metabolomic
profilings of LTB4-S and LTB-R, both of which were cultured in
medium without kanamycin, were analyzed by gas chromatog-
raphy-mass spectrometry (GC-MS). Eight biological and two
technical replicates were performed, covering 63 metabolites
in each strain (Figure S1B). The Z scores for LTB4-S were
17.5 to +13.8 (Figure S1C). Forty-nine of 63 metabolites
(77.8%) showed significant difference (p < 0.01) corresponding
to a false discovery rate of 3.2%, with 19 metabolites at lower
abundance and 29 at higher abundance in LTB4-R. Unsuper-
vised hierarchical clustering and Z scores were used to rank
metabolites whose abundance differed significantly in the two
strains (Figures 1A and 1B). Independent component analysis
identified two principal components, IC01 and IC02, where
IC01 discriminates between the two strains, and IC02 discrimi-
nates within each strain (Figure 1C). Glucose abundance was
suppressed to a greater extent in LTB4-R than all other metabo-
lites tested and may have the most impact (Figures 1B, 1D and
S1D). However, the most strongly impacted KEGG pathway is
alanine, aspartate, and glutamate metabolism (Figure 1E).
Decreased abundance of alanine and glutamate was observed
(Figure 1B), with higher impact on alanine (Figures 1D and
S1D). The concentration of alanine and glucose modulates the
concentration of NADH; consistent with this, NADH abundance
was lower in LTB4-R than in LTB4-S (Figure S1E). These results
prompted us to explore whether the suppressed levels of alanine
and glucose are useful biomarkers of antibiotic resistance and
whether the phenotype of LTB4-R cells changes in the presence
of exogenous alanine and/or glucose.
Exogenous Metabolites Alter Susceptibility of
Drug-Resistant E. tarda to Kanamycin
An earlier study reported that exogenous glucose stimulates up-
take of aminoglycoside antibiotics by E. coli persisters (Allison
et al., 2011). Here, we tested whether two metabolites, alanine
or/and glucose, suppressed in LTB4-R, can be used to kill
drug-resistant E. tarda with kanamycin including LTB4-R and
E. tarda EIB202. EIB202 is a wild multidrug-resistant strain car-
rying a 43.7 kbp conjugative plasmid that confers resistance to
tetracycline, streptomycin, sulfonamide, and chloramphenicol
(Figure S2A) (Wang et al., 2009). The two drug-resistant bacteria
were co-incubatedwith alaninewith or without glucose and chal-
lenged with an antibiotic, because we predicted the two metab-
olites might act in a synergistic manner, by virtue of their ability
to stimulate amino acid and carbon metabolisms, respectively.
As predicted, cell survival decreased with increasing dose of
alanine (Figure 2A), glucose (Figure 2B), or alanine plus glucose
(Figures 2C and 2D), when grown in the presence of kanamycin.
Relative to LTB4-R cells grown in the presence of 1,000 mg kana-
mycin alone, cell survival decreased 101-, 3,228-, or 276,000-
fold in the presence of 40 mM alanine, 10 mM glucose, or both
(Figure 2E); cell survival of LTB4-R and EIB202 was 201-, 927-,
and 123,600-fold and 527-, 2,916-, and 283,089-fold lower for
cells grown in the presence of kanamycin plus alanine, glucose,
or both, respectively (Figure S2B).
Similar experiments were performed with three other E. tarda
wild strains, WY28, WY37, and ATCC15947, and three other
LTB4-S-derived the beta-lactam ampicillin-, the quinolone balo-
floxacin-, and the tetracyclins tetracycline-resistant strains.250 Cell Metabolism 21, 249–261, February 3, 2015 ª2015 Elsevier InMinimum inhibitory concentration of these strains is shown in
Figures S2A and S2C, respectively. The results were similar to
those observed with LTB4-R and EIB202 (Figure S2D), suggest-
ing a common mechanism in glucose and/or alanine-mediated
drug susceptibility. A more detailed analysis of cell survival of
EIB202 was performed by titrating the metabolite concentration,
counting the number of surviving cells over time, and generating
a two-dimensional heat map (Figure S3A) since EIB202 is a wild
strain with multidrug resistance. The degree of synergy was
calculated using the combination index (CI) algorithm of Chou
and Talalay (Chou and Talalay, 1981), revealing CI97 values
0.066–0.197 for kanamycin and alanine (Table S1A), 0.053–
0.192 for kanamycin and glucose (Table S1B), and 0.0442–
0.106 for alanine and glucose (Table S1C). Synergy was also
analyzed using isobolograms, confirming the above results.
Optimal conditions to promote kanamycin sensitivity and the
highest level of synergy are revealed in Figure S3A. The dose-
reduction index (DRI) for kanamycin is presented in Tables
S1D–S1F. At 97% effective dose ED97, for kanamycin with
alanine (1:8), glucose (1:2), or both, the DRI is 93.6%, 93.7%,
or 88.1%, respectively. Alanine and/or glucose also potentiated
gentamicin, an aminoglycoside antibiotic to replace kanamycin,
to eliminate EIB202 (Figure S3B). However, only weak effect was
detected when aminoglycoside antibiotic kanamycin was re-
placedwith the beta-lactam ampicillin, ceftazidime, or the quino-
lone balofloxacin (Figure S3B), which is similar to previously
reported data (Allison et al., 2011). Replacement of alanine or
glucose with threonine or maltose showed similar effects, but
not isoleucine (Figure S3C). Correspondingly, lower PMF was
detected in cells incubated with isoleucine than with threonine
or maltose (Figure S3D). To exclude the possibility that the ef-
fects of exogenous metabolite were associated with growth
state, survival rate of EIB202 was monitored in M9 medium or
M9/LB mixed medium supplemented with or without metabolic
stimuli (glucose or alanine). As shown in Figure S3E, the only fac-
tor that makes the survival rate different is the supplementation
of metabolic stimuli together with kanamycin rather than meta-
bolic stimuli alone (Figure S3E).
Treating Clinically Relevant Bacterial Biofilms and
Persisters
Infection with bacterial biofilms and persisters are a significant
concern in the clinical environment (Cohen et al., 2013; Corona
and Martinez, 2013; Drenkard and Ausubel, 2002); therefore,
it would be clinically useful if biofilms and persisters were sus-
ceptible to killing by kanamycin in the presence of alanine and/
or glucose. To test this possibility, fish-derived pathogenic
E. tarda EIB202 and human-derived pathogenic E. tarda
ATCC15947 were cultured in vitro as biofilms in the presence
of kanamycin without or with alanine and/or glucose. In this sys-
tem, EIB202 and ATCC15947 biofilm growth was inhibited 372-
and 162-fold by kanamycin plus alanine and glucose (Figure 2F),
respectively. Pathogenic E. tarda EIB202 and ATCC15947 bio-
films were also injected via catheter into the urinary tracts of
mice, and in this in vivo system, kanamycin plus alanine and
glucose also inhibited infection in the urinary tract and sup-
pressed spread of infection to kidneys (Figures 2G and 2H). In
all cases, cell killing required kanamycin and was more severe
in the presence of alanine and glucose.c.
Figure 1. Metabolic Profiling and Bioinformatics Analysis of Drug-Sensitive—LTB4-S—and Drug-Resistant—LTB4-R—E. tarda Strains
(A) Heatmap showing relative abundance ofmetabolites (Wilcoxon p < 0.01) inE. tarda LTB4-R and LTB4-S. Heatmap scale (green to red: low to high abundance)
is shown at bottom.
(B) Z scores (standard deviation from average) corresponding to data in (A). Each point represents one technical repeat in one metabolite. Black, LTB4-S; blue,
LTB4-R.
(C) Independent component analysis (ICA) of E. tarda LTB4-S and LTB4-R. Each dot shows one technical replicate.
(D) Hierarchical clustering of decreased abundance of metabolites in E. tarda LTB4-R.
(E) Enriched pathways in E. tarda LTB4-R (p < 0.01).
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Figure 2. Effect of Exogenous Alanine and/or Glucose on Susceptibility of Antibiotic-Resistant E. tarda, Biofilms, and Persisters to
Kanamycin
(A and B) LTB4-R or EIB202 were incubated with increasing concentrations of alanine (A) or glucose (B) for 6 hr in the presence of kanamycin.
(C and D) Synergic effects of alanine and glucose on bacterial survival. Experiments were performed similarly to (A) and (B), except for the presence of 10 mM
glucose (C) or 40 mM alanine (D).
(E) Percent survival of LTB4-R in the presence or absence of metabolite(s) in the indicated kanamycin concentrations.
(F) Percent survival of EIB202 and ATCC15947 in biofilms treated with 40 mg and 30 mg/ml kanamycin, respectively, in the presence of alanine and/or glucose as
indicated.
(G) Mouse urinary tracts were catheterized and infected with EIB202 and ATCC15947. Mice were treated with 3,000 mg/kg kanamycin as indicated and 3 g/kg
alanine, 1.5 g/kg glucose, or both twice daily for 3 days.
(H) Kidney biopsies were obtained, and cfu/g kidney tissue was measured for mice treated as indicated.
(I) Percent survival of EIB202 and ATCC15947 persisters in the presence or absence of alanine and/or glucose plus kanamycin.
Results are displayed as mean ± SEM, and significant differences are identified (*p < 0.05, **p < 0.01; which caused by dose gradient are not marked) as
determined by Student’s t test. Three biological repeats were carried out.Bacterial persisters are a small phenotypically different sub-
population of specialized survivor cells found within biofilms
and planktonic bacterial populations. They have been shown
to be highly tolerant to antimicrobials and have been reported
to be the cause of persistent and difficult-to-treat infections (Co-
hen et al., 2013). Here, the frequency of persisters of EIB202 and
ATCC15947 decreased 2,320- and 1,373-fold in the presence of
kanamycin plus alanine and glucose, respectively (Figure 2I).
Other relevant human and/or fish pathogens, including Vibrio
parahaemolyticus, Klebsiella pneumonia, methicillin-resistant
Staphylococcus aureus (MRSA), and Pseudomonas aeruginosa,
are also susceptible to killing by kanamycin plus alanine and
glucose (Figure S3F). These findings suggest that kanamycin
plus alanine and glucose could be useful for managing or pre-252 Cell Metabolism 21, 249–261, February 3, 2015 ª2015 Elsevier Inventing infection with drug-resistant pathogens, many of which
cause diseases in humans and other economically and/or envi-
ronmentally important species.
Increased PMF Stimulates Uptake of Antibiotic
Glucose promotes uptake of aminoglycoside antibiotics by
increasing PMF (Allison et al., 2011). A similar mechanism was
observed here (Figures 3A–3C and S4A). Specifically, higher
concentration of NADH, higher PMF, and higher kanamycin-
induced cell death were detected in in E. tarda EIB202 incubated
with exogenous alanine and/or glucose, effects that abolished
by carbonylcyanidem-chlorophenyl hydrazone (CCCP). To iden-
tify PMF as the leading factor for glucose- and/or alanine-medi-
ated bacterial killing, we validate this by four ways. First, thec.
kanamycin-mediated killing was sensitive to pH, indicating that
the killing is attributed to PMF (Figure S4B) (Allison et al.,
2011). Second, the level of pyruvate rather than lactate was
elevated with increased concentration of alanine and/or glucose.
Therefore, the pyruvate/lactate ratio was increased in a dose-
dependent manner (Figures 3D and S4C). This suggests the pri-
ority to generating pyruvate over lactate, which is consistent with
the elevated NADH and PMF. Third, the expression of NuoI and
NuoE, the two enzymes for NADH oxidation, and respiratory
chain dehydrogenase activity, which contribute to cytochrome
quinol oxidases activity, were increased by exogenous alanine
and/or glucose (Figures 3E and 3F). Forth, three inhibitors—rote-
none, antimycin A, and NaN3—of the aerobic respiratory chain
partly abolished increased PMF and acquired sensitivity to kana-
mycin (Figures 3G–3I and S4D), in which rotenone inhibits the
transfer of electrons from iron-sulfur centers in complex I to
ubiquinone and antimycin A and NaN3 are inhibitors of the ubiq-
uinoloxidation and the oxidases, respectively. One noticeable
observation is that glucose but not alanine stimulated PMF and
partially reverted the phenotype of drug resistance in E. tarda un-
der anaerobic condition (Figures 3J and S4E), a result consistent
with the fact that glucose supports anaerobic respiration.
Alanine and/or glucose stimulate antibiotic uptake. Intracel-
lular concentration of kanamycin was significantly higher in
E. tarda grown in the presence of alanine and/or glucose than
in the absence of alanine and glucose (Figure 3K). And lower
kanamycin was detected in LTB4-R than in LTB4-S in medium
with one-half MIC drug of LTB4-S, which may be owed to higher
rate of drug exported and/or lower rate of drug uptake in the
resistant strain. The absence of alanine and glucose led to
9.5 ng/ml drug difference between LTB4-R and LTB4-R (36.5
versus 46.0 ng/ml), whereas alanine and/or glucose promote
more 65–123 ng/ml and 113–231 ng/ml drug uptake in LTB4-R
and LTB4-S, respectively, suggesting the increased drug uptake
overcomes the effects by drug efflux pump (Figure 3L). It is sup-
ported by the events that no mutations of AcrAB-TolC were de-
tected (data not shown), and alanine and/or glucose did not
affect expression of TolC (Figure S4F). These results suggest
that increased PMF contributes to the mechanism by which
alanine and/or glucose stimulates uptake of kanamycin by
E. tarda and decreases cell survival.
Exogenous Metabolites Promote Metabolic Flux of the
TCA Cycle
We propose that exogenous alanine or glucose acts in a manner
to revert multidrug-resistant E. tarda EIB202, which contributes
to elevation of NADH and PMF. To investigate this possibility,
metabolic profiles (63 metabolites, 5 biological and 2 technical
replicates) of EIB202 were compared in the presence and
absence of alanine, glucose, or alanine plus glucose. Data
were analyzed as described above, and the results are pre-
sented in Figures 4, S5, and S6. The four groups are clearly
separately using ICA (Figure 4A). Based on Z score analysis,
exogenous alanine, glucose, or alanine plus glucose significantly
altered the metabolic state (Figure S5A). Forty-eight, fifty-one,
and forty-nine of the 63 metabolites (76.20%, 80.95%, and
77.78%) had significant change in abundance, corresponding
to a false discovery rate of 5.9%, 8.3%, and 16.3% (Figures
S5B–S5D). Unsupervised hierarchical clustering and pathwayCell Menrichment analysis identified 16 biological pathways (Figures
S5E and S5F), out of which the first three impact values are listed
in Figure 4B. The largest effects were observed on decreased
amino acid metabolism (glycine, serine, asparagine, valine, and
proline) (Figure S6) and increased the TCA cycle (Figure 4C).
The synergy of alanine and glucose increased higher production
of succinate, malate, and citrate, but not fumarate, than alanine
or glucose alone (Figure 4D). These results indicate that the
metabolic flux of the TCA cycle increases in the presence of
alanine and/or glucose.
Recently developed NTFD (non-targeted tracer fate detection)
is a powerful tool to provide information about relative flux
magnitudes into each metabolite pool by determining the mass
isotopomer distribution for all labeled compounds (Hiller et al.,
2011;Walther et al., 2012). To further demonstrate the promotion
in the TCA cycle as a result of exogenous alanine and/or glucose,
we performed 13C3-alanine and
13C6-glucose tracer experiments
in EIB202 by GC-MS (Table S2). As shown in Figures 4C and
S6B, 13C3-alanine or
13C6-glucose is converted by acetyle-CoA
synthase to produce labeled acetyl-CoA, which provides an
acetyl group to citrate, succinate, fumarate, malate, and aspar-
tate to generate M2 label in the initial cycle. In the second cycle,
both labeled and unlabeled acetyl-CoA are entered into the TCA
cycle and are added to theM2 label to generate M3 andM1 label
through oxidative decarboxylation, respectively. Since the unla-
beled acetyl-CoA has exogenous and endogenous sources, M1
is higher than M3 label. Similarly, the labeled acetyl-CoA adding
to M3 label would produce M4 label. Since an equal amount of
M2 is required for the M3 generation, (M1 +M3) / (M2 +M3) ratio
of each pool represents relative flux for that metabolite in the
TCA cycle (yTCA/yALA, yGLC, or yBOTH), where yTCA refers to the
turnover of a particular metabolite pool and yALA and/or yGLC re-
fers to the flux of alanine and/or glucose carbon atoms to the
TCA cycle. M1 label is lower in citrate than in succinate, fuma-
rate, or malate pools, which is due to the oxidative decarboxyl-
ation of a-ketoglutarate. Low M1-fumarate and -aspartate and
high M1-malate as well as low M2- and high M4-malate in the
13C3-alanine tracer experiment suggest glyoxylic acid cycle
may be involved in the flux, which is supported by elevated fatty
acid synthesis in the 13C3-alanine (data not shown). Thus, the
relative flux for 13C3-alanine in the malate of glyoxylic acid cycle
can be represented by (M1 + M3) / (M2 + M4 + M3) (yMALAT/yALA)
(Figure S6C). In addition, most of M2-labeled metabolites are
from labeled acetyl-CoA and unlabeled oxaloacetate. Although
oxaloacetate and glutamate are interconverted to each other
via alanine aminotransferase, the detection of few labeled gluta-
mate indicates that the labeled metabolites are not converted to
glutamate. The enriched M2-aspartate alone in aspartate pool
indicates that L-aspartate may contribute to M2 regulation of
the TCA cycle through fumarate and oxaloacetate (Figure 4C).
In summary, the tracer experiments suggest that the exogenous
glucose and/or alanine are converted to acetyl-CoA and then flux
to the TCA cycle, which is regulated by glutamate, aspartate, and
glyoxylic acid cycle.
Promotion of the TCA Cycle Is Required for Restoring
Sensitivity to Kanamycin
To understand how the TCA cycle was activated by alanine and/
or glucose and also further validate the finding that activation ofetabolism 21, 249–261, February 3, 2015 ª2015 Elsevier Inc. 253
Figure 3. Effect of Exogenous Alanine and/or Glucose on NADH, PMF, and Intracellular Kanamycin
(A) Intracellular NADH concentration in EIB202 in the presence of alanine and/or glucose as indicated.
(B) PMF in EIB202 in the presence of alanine and/or glucose and effect of CCCP as indicated.
(C) Percent survival of EIB202 in the presence or absence of CCCP and in the presence of alanine and/or glucose.
(D) The pyruvate/lactate ratio of EIB202 in the presence of alanine and/or glucose.
(E) Western blot for detection of NuoL and NuoF expression in the presence of alanine and/or glucose. Protein loading amounts were normalized to SDS-
PAGE gel.
(F) Activity of respiration chain dehydrogenase in the presence of alanine and/or glucose.
(G–I) Percent survival of EIB202 in the presence or absence of increasing doses of rotenone (G), antimycin A (H), and NaN3 (I) and in the presence of alanine and/or
glucose.
(J) Percent survival of EIB202 cultured under aerobic or anaerobic conditions in the presence of alanine and/or glucose as indicated.
(legend continued on next page)
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Figure 4. Metabolic Pathway Analysis
(A) Independent component analysis of cells
grown in the presence or absence of alanine and/
or glucose.
(B) Enriched pathways in the presence of alanine
and/or glucose.
(C) Elevated abundance of metabolites (in red) in
the TCA cycle and mass isotopomer distributions
for 13C-labeled alanine or glucose detected in a
nontargeted manner (histogram) in the presence
of alanine, glucose, or both. Elevation of glutamate
is detected only in the presence of glucose and
plus alanine.
(D) Scatter plot showing normalized abundance of
four TCA cycle metabolites. Each dot shows a
technical replicate.
*p < 0.05 and **p < 0.01 as determined by
Student’s t test.the TCA cycle is required for the potential, we evaluated expres-
sion and activity of enzymes in the TCA cycles by western blot
and enzyme inhibitors (Figure 5A). The expressions of succinyl-
CoA synthetase b subunit (SucC) and citrate synthase (GltA)
were increased with alanine and/or glucose dose (Figure 5B).
Similarly, the activity of three key enzymes, citrate synthase
(CS), isocitrate dehydrogenase (ICDH), and a-oxoglutarate de-(K) Intracellular kanamycin concentration in EIB202 and ATCC15947 in the presence of alanine and/or gluco
(L) Comparison of intracellular kanamycin between LTB4-R and LTB4-S in the presence of alanine and/or g
Results in (A)–(E) and (G)–(L) are displayed as mean ± SEM, and significant differences are identified (*p < 0.05
marked) as determined by Student’s t test. Three biological repeats were carried out (A)–(L).
Cell Metabolism 21, 249–261hydrogenase (OGD), of the TCA cycle
were elevated in the presence of alanine
and/or glucose (Figure 5C). We further
validate this by using two inhibitors, bro-
mopyruvate or malonate. Bromopyruvate
is an active-site-directed inhibitor of the
pyruvate decarboxylase (El), a compo-
nent of the pyruvate dehydrogenase
complex, which converts pyruvate to
acetyl-CoA (Figure 5A). Malonate is a
competitive inhibitor of succinate dehy-
drogenase (Figure 5A). As shown in Fig-
ure 5C, the activities of the three enzymes
were elevated in the presence of alanine
and/or glucose. Bromopyruvate inhibited
the activities of CS and ICDH in the pres-
ence of glucose and glucose plus alanine
but not alanine alone. Comparatively, the
activity of OGD was inhibited at all cases,
indicating it may play more critical roles
than CS and ICDH. These enzymes
were affected because the rate of inhibi-
tion by bromopyruvate was significantly
increased in the presence of pyruvate
(Lowe and Perham, 1984; Brown et al.,
1997), which caused less pyruvate and
then acetyl-CoA to enter the TCA cycle
and affect the activity of these enzymes.Malonate and bromopyruvate inhibited NADH and PMF genera-
tion promoted by alanine and/or glucose (Figures 5D and 5E).
Furthermore, malonate rescued higher viability of EIB202 than
bromopyruvate (Figures 5F and 5G), which is consistent with
the fact that pyruvate decarboxylase regulates concentration
of pyruvate as a source of the TCA cycle, whereas succinate
dehydrogenase plays a role in the TCA cycle and generation ofse as indicated.
lucose as indicated.
, **p < 0.01; which caused by dose gradient are not
, February 3, 2015 ª2015 Elsevier Inc. 255
Figure 5. Effect of Exogenous Alanine and/or Glucose on Enzymes of the TCA Cycle
(A) Superimposed onmetabolic pathways related to glucose, alanine, and the TCA cycle. PDH, pyruvate dehydrogenase; GltA, citrate synthase; ICDH, isocitrate
dehydrogenase; OGD, oxoglutarate dehydrogenase complex; SucC, succinyl-CoA synthetase b subunit; SDH, succinate dehydrogenase.
(B) Western blot analysis for SucC and GltA expression in the increasing concentration of alanine and/or glucose.
(C) Activity of three key enzymes of the TCA cycle in the presence or absence of exogenous alanine and/or glucose and effect of bromopyruvate.
(legend continued on next page)
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PMF. Our findings indicate that promotion of the TCA cycle by
substrate activation is required for restoring bacterial sensitivity
to kanamycin.
a-Oxoglutarate Promotes Activity of a-Oxoglutarate
Dehydrogenase and Elevates Bacteria to Kanamycin
Susceptibility
The above experiments demonstrate that OGD is especially
crucial for the killing potential. We reason that the similar result
is obtained when activity of OGD elevates. To test this idea, we
used a-oxoglutarate, the substrate of OGD (Figure 6A), to pro-
mote the activity of the enzyme. Results showed that the enzyme
activity elevatedwith increasing a-oxoglutarate dose (Figure 6B).
The viability of EIB202 cells was approximately 1,000-fold lower
in the presence of 1.6 mg/ml kanamycine and 5 mM a-oxogluta-
rate than in the presence of kanamycin without a-oxoglutarate or
a-oxoglutarate without kanamycin (Figure 6C). Exogenous a-ox-
oglutarate increased intracellular NADH of EIB202, which was
abolished by malonate (Figure 6D). Elevated PMF was also de-
tected in a dose-dependent manner (Figure 6E). CCCP reduced
PMF, abrogated the ability of exogenous a-oxoglutarate to in-
crease PMF (Figure 6F), and increased survival in the presence
of kanamycin (Figure 6G). The intracellular concentration of
kanamycin was measured in EIB202 cells in the presence and
absence of a-oxoglutarate. Results suggest that a-oxoglutarate
stimulates uptake of kanamycin (Figure 6H), which is similar to
the result obtained using alanine or glucose. These results indi-
cate that increased activity of a-oxoglutarate dehydrogenase
may promote bacterial susceptibility to kanamycin, which further
supports the conclusion that promotion of the TCA cycle by sub-
strate activation may potentiate action of kanamycin in elimi-
nating antibiotic-resistant bacteria.
DISCUSSION
A strategy for overcoming bacterial resistance to antibiotics
is described that bypasses the need for discovery or design
of novel drugs or reagents. This strategy uses non-toxic com-
pounds to modulate the metabolome of antibiotic-resistant
bacteria, promote the TCA cycle, increase PMF, and stimulate
transport of extracellular antibiotics through the bacterial cell
wall/membrane into the intracellular environment. The first step
in our study was to characterize the antibiotic-resistant metabo-
lome and identify low- (or high-) abundance metabolites that
correlate with antibiotic resistance.
In this study, we observe that susceptibility to antibiotics is
restored when the suppressed metabolites are supplied in the
growth media. A mechanism for this effect is proposed: namely,
increased flux through the TCA cycle, increased PMF, increased
drug uptake, and increased killing (Figure 7). Although the
observed effects in resistant strains and proposed mechanism
are similar to those of Allison et al. for persistent bacteria, the
mechanism of the metabolic pathway for PMF production is still(D and E) NADH (D) and PMF (E) in the presence or absence of alanine and/or g
(F and G) Percent survival of EIB202 in the presence of kanamycin, alanine,
malonate (G).
Results in (C)–(G) are displayed asmean ± SEM, and significant differences are ide
determined by Student’s t test. Three biological repeats were carried out.
Cell Munknown (Allison et al., 2011). To expand this, we showed that
NADH, specifically generated from TCA cycle (Figures 4, 5,
and 6), is the source of proton to generate PMF, which is attrib-
uted to elevated activity of the three key metabolites in the TCA
cycle by substrate activation (Figures 5 and 6) and thereby is
responsible for the increased killing. Association of the TCA cy-
cle with antibiotic resistance has been reported (Kohanski et al.,
2007, 2008, 2010; Lin et al., 2014). The present study indicates
that we may regulate the TCA cycle to promote antibiotic uptake
and then increase killing. Moreover, we not only test carbon
sources as previously described but also confirmed the capa-
bility of nitrogen source and amino acids, in potentiating antibi-
otic to kill bacteria effectively, which is never tested by others.
The high-level synergy of two different types of metabolites
may relate to their metabolic pathways. On one hand, alanine
is metabolized to pyruvate as glucose dose. Pyruvate is con-
verted to acetyl-coenzyme A, which is the major upstream input
for the TCA cycle. On the other hand, alanine transfers the amino
group to a-ketoglutarate by alanine aminotransferase and pro-
duces pyruvate and L-glutamate. Glutamate is the only amino
acid that undergoes rapid oxidative deamination by glutamate
dehydrogenase, which uses NAD or NADP as a coenzyme to
generate a-ketoglutarate (Sharkey et al., 2013). Thus, this syn-
ergy may contribute to a-ketoglutarate regulation and elevated
NADH production, which is supported by our tracer experiment
that glutamate fluxes from glutamate to a-ketoglutarate oneway,
though the exact mechanism needs further investigation.
The presence of an effective penetration barrier in bacteria has
been regarded as a major problem largely responsible for the
lack of progress in the field (Lewis, 2013). The present study
demonstrates that alanine and/or glucose subvert the penetra-
tion barrier and potentiate aminoglycoside antibiotic uptake to
eliminate antibiotic-resistant strains. Indeed, the effects related
to uptake lead to elevation of intracellular antibiotic by several-
fold so that the high concentration of drug surmounts other bac-
terial antibiotic-resistant mechanisms, including the multidrug
efflux pump, and thus effectively exerts the antibacterial effect.
In this study, we sequenced three genes, AcrA, AcrB, and
TolC, whose products consist the major efflux pump conferring
intrinsic resistance to antibiotics in many pathogens, to exclude
the possible acquired gene mutations contributing to decreased
intracellular kanamycin in drug-resistant bacteria. Although mu-
tations in other unknown genesmight be present, which requires
further investigation, our approach still shows an effective way
to combat antibiotic-resistant bacteria by promoting uptake of
antibiotics.
The experimental system reported here demonstrates rever-
sion of multidrug-resistant E. tarda to susceptibility to killing by
kanamycin. In four multidrug-resistant wild E. tarda strains with
or without an antibiotic-resistant plasmid and four LTB4-S-
derived strains with different antibiotic-resistant mechanisms,
exogenous alanine and/or glucose effectively restores suscepti-
bility to kanamycin. We believe that our approach has generallucose and effect of malonate or bromopyruvate.
and/or glucose and the increasing concentrations of bromopyruvate (F) or
ntified (*p < 0.05, **p < 0.01; which caused by dose gradient are not marked) as
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Figure 6. Exogenous a-Ketoglutarate Elevates Susceptibility of E. tarda to Kanamycin
(A) The overall reaction accomplished by oxoglutarate dehydrogenase complex (OGDC).
(B) Effect of exogenous a-ketoglutarate on activity of a-oxoglutarate dehydrogenase of EIB202.
(C) EIB202 were incubated in the presence of kanamycin and increasing concentrations of a-ketoglutarate for 6 hr.
(D) Intracellular NADH in EIB202 in the presence or absence of a-ketoglutarate and/or malonate.
(E) PMF of EIB202 in the increasing concentration of a-ketoglutarate.
(F) PMF in EIB202 in the presence or absence of a-ketoglutarate and/or CCCP.
(G) Percent survival of EIB202 in the presence or absence of CCCP, kanamycin, and/or a-ketoglutarate.
(H) Intracellular kanamycin in EIB202 in the presence or absence of a-ketoglutarate. Results are displayed as mean ± SEM, and significant differences are
identified (*p < 0.05, **p < 0.01; which caused by dose gradient are not marked) as determined by Student’s t test. Three biological repeats were carried out.relevanceandmaybeuseful in future for treatingclinically relevant
diseases caused by antibiotic-resistant bacteria. For example,
gentamicin also kills E. tarda in the presence of alanine, and the
effect is also observed in other bacterial strains including multi-
drug-resistant strains V. parahaemolyticus, K. peneumoniae,
P. aeruginosa, and a superbug MRSA. The role of metabolites in
antibiotic resistance has been reported previously (Vega et al.,
2012, 2013; Lee et al., 2010; Gusarov et al., 2009; Shatalin et al.,
2011; Bernier et al., 2011), but the fact that exogenous metabo-
lites restore susceptibility to antibiotics and the mechanism by
which this occurs are important findings.
In summary, we demonstrate that the bacterial susceptibility
to antibiotics is strongly associated with metabolic states and
that specific metabolic profiles are correlating with certain
antibiotic resistance. Therefore, chemicals that revert themetab-
olomics profile of an antibiotic-resistant strain to that of an anti-
biotic-sensitive strain could potentially revert the antibiotic resis-
tance. Our study proposed an approach to identify metabolic
modulator through investigation of metabolomics, by which
crucial modulators can be used for therapeutic purpose.
EXPERIMENTAL PROCEDURES
Antibiotics, Chemicals, and Antibodies
All antibiotics were obtained from Shanghai Sangon Biological Engineering
Technology & Services Co. Ltd. Antibiotics were filtered with a 0.22 mm pore258 Cell Metabolism 21, 249–261, February 3, 2015 ª2015 Elsevier Insize hydrophilic PVDF membrane. All other chemicals were purchased from
Sigma Aldrich (Sigma). CCCP, rotenone, and antimycin A were dissolved in di-
methylsulphoxide, and sodium azide was dissolved in water. All reagents were
stored at 20C. Antibodies were obtained from Chenxue Biological Corp.
Bacterial Strains and Growth Conditions
All bacterial species in this study were obtained from the collection of our lab-
oratory. LTB4-S-derived strains including LTB4-R were selected by sequential
propagations in LB broth with respective antibiotics. The sensitivity to antibi-
otics was evaluated by the minimum inhibitory concentration, which was
determined by serial 2-fold dilution of antibiotics. All bacterial cultures were
grown in LB medium from frozen stock in a shaker bath for 24 hr at 30C for
V. parahaemolyticus and E. tarda strains, except for ATCC15947, and at
37C for the other bacteria.
Metabolomic Profiling
Sample preparation and GC-MS analysis were carried out as previously
described (Cheng et al., 2014).
Statistical Analysis and Sample Pattern Recognition
Initial peak detection and mass spectral deconvolution were performed using
XCalibur software (Thermo Fisher, version 2.1). Metabolites were identified
using spectral matching and retention indexes from National Institute of
Standards and Technology (NIST) library using the NIST MS search 2.0. After
the removal of any known artificial peaks and merger of the same com-
pounds, the internal standard allows normalization of the resulting data.
The peak intensities were normalized to form a single matrix with Rt-m/z
pairs (retention time-mass charge ratio pairs) for each file in the data set.
This file was then used for further analysis as described previouslyc.
Figure 7. Proposed Mechanism for Cell Killing in the Presence of Alanine and/or Glucose plus Kanamycin
Alanine and/or glucose promote the TCA cycle by substrate activation and lead to elevated concentration of NADH. The NADH is oxidized through electron
transport chain to generate PMF. The PMF facilitates aminoglycoside uptake, thereby elevating intracellular antibiotic concentration and effectively killing
antibiotic-resistant bacteria.(Sreekumar et al., 2009). Z score analysis scaled each metabolite according
to a reference distribution.
Multivariate statistical analysis included independent component analysis
(ICA) (http://metagenealyse.mpimp-golm.mpg.de/). ICA was used to discrim-
inate sample patterns, identify themetabolites associated with resistance, and
minimize the interindividual variation’s influence. Principal component analysis
(PCA) was applied to reduce the high dimension of the data set. GraphPad
Prism v5.01 was used to draw the histogram and the scatter plot. We analyzed
the differential metabolites to their respective biochemical pathways as out-
lined in the Kyoto Encyclopedia of Genes and Genomes (KEGG, release
41.1, http://www.genome.jp/kegg) and MetPA (http://metpa.metabolomics.
ca/MetPA/faces/Home.jsp), which provides impact factors as an index.
Antibiotic Bactericidal Assays
Antibiotic bactericidal assay was carried out as previously described (Allison
et al., 2011). In brief, a single bacterial colony was grown in 50 ml LB broth
in 250 ml flasks for 24 hr at 30C. After centrifugation at 8,000 3 rpm for
5 min, samples were washed twice with 30 ml sterile saline and re-suspended
in M9 minimal media supplemented with 10 mM acetate, 1 mM MgSO4, and
100 mM CaCl2 to 0.2 at OD600. Reaction samples were added to metabolites
and antibiotic and incubated at 30C for 6 hr. The use of M9 medium offers
us the advantage to test the effects of different metabolites on antibiotic-resis-
tant strains in a reliable way, by which potential confounding factors would not
be present as in more complex medium. In all experiments with CCCP, sam-
ples were pre-treated with the proton ionophore for 5 min before adding anti-
biotic. After incubation, 100 ml aliquot samples were periodically removed,
serially diluted, and plated (10 ml aliquots) onto LB agar plates. The plates
were cultured at 30C or 37C for 18–22 hr depending on bacteria species.
Only those dilutions yielding 20–200 colonies were enumerated to calculate
colony-forming units (cfu). Percent survival was determined by dividing the
cfu obtained from a treated sample by the cfu obtained from control.
Isotope Tracer Experiment
The effects of nine 13C-labeled tracers (six glucose and three alanine) on flux
estimation precision were investigated as previously described (Hiller et al.,
2010). In brief, EIB202 was cultured using a 1:1 mixture (total 20 mM alanine
and/or 10 mM glucose) of unlabeled substrate and [U-13C3]alanine and/or
[U-13C6]glucose. Three biological replicates were performed for each growth
condition. GC-MS was performed using an Agilent 7890A GC equipped with
a 30 m DB-35MS capillary column connected to an Agilent 5975C MS oper-Cell Mating under electron impact (EI) ionization. The effectiveness of each tracer
was gauged using the software downloaded from the internet (Hiller et al.,
2013). The software provides the mass isotopomer distribution (MID) data of
all labeled compounds detected in the GC-MS data. Labeled compounds
were identified from theMID data, whichwere used for estimation of metabolic
fluxes. The estimation was carried out by the tracing of labeled atoms present
in an externally supplied compound as it is metabolized. Both the spectrum
obtained from the labeled chromatogram and the spectrum obtained from
the unlabeled chromatogram were normalized by their total signal. The
detailed analysis is described in Figure S6.
Anaerobic Experiments
E. tarda EIB202 cells were re-suspended in M9 medium with an OD600 of 0.2.
The re-suspended cells were mixed with kanamycin plus alanine and/or
glucose and incubated in an anaerobic jar (MART Microbiology) at 30C for
6 hr. The cultures were spotted onto LB agar plates to determine cfu/ml as
described above.
Measurement of Membrane Potential
The membrane potential was examined via BacLight Bacterial Membrane Po-
tential Kit (Life Technologies) as previously described (Allison et al., 2011).
NADH Measurements
E. tarda culture was diluted to OD600 of 0.2 and incubated with metabolite(s) at
30C for 6 hr. Cell pellets were washed and re-suspended with NADH extrac-
tion buffer. Heat extracts were performed at 60C for 5 min. Buffer and NAD
extraction buffer were added to neutralize the extracts. The cells were vor-
texed and spun down at 14,000 rpm for 5 min. Supernatant was collected
for the EnzyChrom NAD/NADH Assay Kit (BioAssay Systems).
Measurement of Intracellular Kanamycin
Bacterial cells were incubatedwith kanamycin or kanamycin plusmetabolite(s)
at 30C for 6 hr. The cells were washed and re-suspended in sterile saline and
adjusted to OD600 of 1.0. Each aliquot of 1 ml sample was sonicated for 3 min
and centrifuged to remove insoluble matters. Kanamycin in supernatants was
quantified with Kanamycin ELISA Rapid Diagnostic Kit (Beijing Clover Tech-
nology Group Inc.). Luminescence intensity was measured on a PerkinElmer
LS55 Fluorescence Spectrophotometer (PerkinElmer). A quartz cuvette with
an optical path length of 10 mm was selected with excitation and emission
at 287 and 450 nm, respectively.etabolism 21, 249–261, February 3, 2015 ª2015 Elsevier Inc. 259
Biofilm Assay and Mouse Infection Assay
Biofilm-formation culture was determined as previously described (Allison
et al., 2011). In brief, 6 mm PE50 catheters (0.58 mm 3 0.96 mm) were inocu-
lated in 1 ml fresh LB and 10 ml cultured stationary phase bacteria, then incu-
bated aerobically for 24 hr at 30C. The medium was changed every 24 hr for a
total of 72 hr. The PE50 catheters were washed five times with 1 ml of sterile
saline to remove loosely adherent cells and planktonic cells. For in vitro exper-
iments, catheters with 1.56 3 106 cfu as biofilm were used for kill bacteria
directly. For in vivo experiments, the biofilm-coated tubing with 1.56 3 106
cfuwas surgically implanted in the urinary tract of female Balb/cmice (4weeks,
weighing 20–25 g). Forty-eight hours after surgery, mice were randomly
divided into seven groups, eight mice for each group, including intraperitoneal
injection with saline, glucose (1.5 g/kg), alanine (3 g/kg), kanamycin (3 mg/kg),
glucose (1.5 g/kg) plus kanamycin (3 mg/kg), alanine (3 g/kg) plus kanamycin
(3 mg/kg), or glucose (1.5 g/kg) plus alanine (3 g/kg) plus kanamycin (3 mg/kg)
for 3 days (twice per day). After the treatment, mice were observed for an addi-
tional 24 hr. Finally, the catheter tubings were removed and bacteria were
collected in 1 ml sterile saline to determine cfu/ml. Meanwhile, kidneys were
obtained to determine bacterial load (cfu/g). Mice were provided by the Center
of Experiment Animal of Sun Yat-sen University. Animal protocols were
approved by the Committee for the Use and Care of Laboratory Animals,
Sun Yat-sen University.
Western Blot Analysis
Bacterial protein samples were resolved on 10% SDS-PAGE and transferred
to nitrocellular membranes (GE Healthcare Life Sciences). The membranes
were incubated with 1:1,000 of the primary rabbit antibodies anti-NouF,
anti-TolC, anti-SucC, and anti-GltA or the primary mouse antibody anti-
NouI, followed by corresponding goat anti-rabbit or rabbit anti-mouse second-
ary antibodies conjugated with horseradish peroxidase. Band intensities were
detected by using a gel documentation system, LAS-3000 (Fujifilm Medical
Systems).
Measurement of Enzyme Activity
Citrate synthase, isocitrate dehydrogenase, and a-ketoglutarate dehydro-
genase were measured by citrate synthase, isocitrate dehydrogenase,
and a-ketoglutarate dehydrogenase activity Colorimetric Assay Kits
(Genmed Scientifics Inc.). In brief, EIB202 cultures were collected, washed,
re-suspended in lysate (from the assay kits), and disrupted by sonic oscil-
lation. Following centrifugation, supernatant was transferred to a new tube,
and a Bradford assay was used to detect protein concentrations. Respira-
tory chain dehydrogenase activity was detected as previously described (Li
et al., 2010).
Pyruvate and Lactate Concentration Detection
Pyruvate and lactate concentrations were detected through Pyruvate and
Lactate Detection Kits, respectively (Nanjing Jiancheng Bioengineering Insti-
tute). In brief, EIB202 cultures were collected, washed, re-suspended with
saline solution, and adjusted to OD600 of 1.0. Aliquots of 1 ml samples were
sonicated for 3 min, and the resulting supernatant was used for detection of
pyruvate and lactate.
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